Takeda Pharmaceutical Company Limited Website

Takeda Pharmaceutical Company Limited

TSE-4502

Basic

  • Market Cap

    ¥6,703.96B

  • EV

    ¥11.71T

  • Shares Out

    1,584.86M

  • Revenue

    ¥4,263.76B

  • Employees

    49,281

Margins

  • Gross

    66.43%

  • EBITDA

    26.68%

  • Operating

    11.57%

  • Pre-Tax

    1.24%

  • Net

    3.38%

  • FCF

    12.69%

Returns (5Yr Avg)

  • ROA

    1.67%

  • ROTA

    17.53%

  • ROE

    4.05%

  • ROCE

    4.47%

  • ROIC

    -8.02%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    ¥4,729.94

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    ¥457.8B

  • Net Debt

    ¥5,005.59B

  • Debt/Equity

    0.75

  • EBIT/Interest

    4.27

Growth (CAGR)

  • Rev 3Yr

    10.06%

  • Rev 5Yr

    15.25%

  • Rev 10Yr

    9.69%

  • Dil EPS 3Yr

    -27.47%

  • Dil EPS 5Yr

    -8.2%

  • Dil EPS 10Yr

    -3.85%

  • Rev Fwd 2Yr

    1.05%

  • EBITDA Fwd 2Yr

    11.52%

  • EPS Fwd 2Yr

    21.56%

  • EPS LT Growth Est

    10.47%

Dividends

  • Yield

  • Payout

    204.15%

  • DPS

    ¥188

  • DPS Growth 3Yr

    1.46%

  • DPS Growth 5Yr

    0.87%

  • DPS Growth 10Yr

    0.44%

  • DPS Growth Fwd 2Yr

    2.99%

Select a metric from the list below to chart it

Mar '15

Mar '16

Mar '17

Mar '18

Mar '19

Mar '20

Mar '21

Mar '22

Mar '23

Mar '24

Mar '25 (E)

Mar '26 (E)

Mar '27 (E)

Total Revenues

3,291,188

3,197,812

3,569,006

4,027,478

4,263,762

Total Revenues % Chg.

56.9%

-2.8%

11.6%

12.8%

5.9%

Cost of Goods Sold, Total

1,120,146

1,013,655

1,127,308

1,253,163

1,431,505

Gross Profit

2,171,042

2,184,157

2,441,698

2,774,315

2,832,257

Selling General & Admin Expenses, Total

964,268

875,514

886,327

997,234

1,053,819

R&D Expenses

492,088

455,765

526,087

633,325

728,617

Amortization of Goodwill and Intangible Assets

407,343

405,229

418,789

485,102

521,525

Other Operating Expenses

10,663

23,602

10,433

38,987

35,059

Other Operating Expenses, Total

1,874,362

1,760,110

1,841,636

2,154,648

2,339,020

Operating Income

296,680

424,047

600,062

619,667

493,237

Interest Expense, Total

-149,010

-130,806

-122,432

-116,973

-115,392

Interest And Investment Income

12,646

2,153

4,763

5,781

11,628

Net Interest Expenses

-136,364

-128,653

-117,669

-111,192

-103,764

Income (Loss) On Equity Invest.

-23,987

76

-15,367

-8,630

6,473

Currency Exchange Gains (Loss)

10,979

-15,575

-3,903

-9,729

-13,612

Other Non Operating Income (Expenses)

-10,631

1,118

-26,119

3,975

-31,520

EBT, Excl. Unusual Items

136,677

281,013

437,004

494,091

350,814

Restructuring Charges

-181,831

-115,875

-83,836

-59,234

-81,358

Merger & Related Restructuring Charges

Gain (Loss) On Sale Of Investments

8,482

22,416

Gain (Loss) On Sale Of Assets

19,871

235,117

8,164

8,901

7,975

Asset Writedown

-60,974

-17,521

-54,421

-62,484

-139,809

Insurance Settlements

8,279

Legal Settlements

-17,401

-20,319

-16,455

-45,212

Other Unusual Items

17,224

902

7,497

-12,145

-39,619

EBT, Incl. Unusual Items

-60,754

366,235

302,571

375,090

52,791

Income Tax Expense

-105,044

-9,936

72,405

58,052

-91,406

Earnings From Continuing Operations

44,290

376,171

230,166

317,038

144,197

Minority Interest

-49

-166

-107

-21

-130

Net Income

44,241

376,005

230,059

317,017

144,067

Net Income to Common Incl Extra Items

44,241

376,005

230,059

317,017

144,067

Net Income to Common Excl. Extra Items

44,241

376,005

230,059

317,017

144,067

Total Shares Outstanding

1,557.8

1,563.4

1,550.4

1,554.5

1,569

Weighted Avg. Shares Outstanding

1,557.2

1,562

1,563.5

1,551.8

1,564.5

Weighted Avg. Shares Outstanding Dil

1,566.2

1,573.5

1,577.2

1,569.9

1,580.3

EPS

28.4

240.7

147.1

204.3

92.1

EPS Diluted

28.3

239

145.9

201.9

91.2

EBITDA

880,329

983,718

1,183,213

1,210,650

1,137,698

Effective Tax Rate

172.9%

-2.7%

23.9%

15.5%

-173.1%